Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moti Ramgopal

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Plos One|June 3, 2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)Michelle Cespedes, Moupali Das, J Carlo Hojilla, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Open Forum Infectious Diseases|March 27, 2023
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 WeeksCharlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
Drugs in R&D|November 24, 2025
Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical TrialAnil Gupta, Maria Teresa Perez-Rodríguez, Yaneicy Gonzalez-Rojas, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Plos One|June 3, 2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)Michelle Cespedes, Moupali Das, J Carlo Hojilla, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Open Forum Infectious Diseases|March 27, 2023
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 WeeksCharlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
Drugs in R&D|November 24, 2025
Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical TrialAnil Gupta, Maria Teresa Perez-Rodríguez, Yaneicy Gonzalez-Rojas, et al.
Pageof 6